Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement
Abstract Background Optimal management of cancer‐associated thrombosis (CAT) in patients with thrombocytopenia remains difficult given competing risks of recurrent thrombosis and increased bleeding. We determine the impact of the ISTH Scientific and Standardization Committee (SCC) guidance on CAT ma...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-05-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rth2.12726 |
| _version_ | 1797761302280536064 |
|---|---|
| author | Nicole Held Benjamin Jung Lisa Baumann Kreuziger |
| author_facet | Nicole Held Benjamin Jung Lisa Baumann Kreuziger |
| author_sort | Nicole Held |
| collection | DOAJ |
| description | Abstract Background Optimal management of cancer‐associated thrombosis (CAT) in patients with thrombocytopenia remains difficult given competing risks of recurrent thrombosis and increased bleeding. We determine the impact of the ISTH Scientific and Standardization Committee (SCC) guidance on CAT management and thrombocytopenia on platelet transfusion, bleeding, and recurrent thrombosis. Methods A retrospective review was performed of patients with CAT and thrombocytopenia who required anticoagulation for VTE for 11 months before and after implementation of the ISTH SCC guidance. Medical records were reviewed to identify the type of VTE event, number of platelet transfusions, incidence of bleeding, and VTE recurrence within pre‐ and postintervention time periods. Results A total of 41 and 80 cases were included in the preintervention and postintervention periods, respectively. The preintervention group showed a trend toward less acute VTE events (39% vs 55%; P = .05). The postintervention period had an increased per‐patient platelet transfusion (median, 2.5 vs 4; P = .05). Nonmajor bleeding was increased in the postintervention group (2% vs 16%; P = 0.03) and included all six (8%) major hemorrhages (P = .09). There was numerically less recurrent thrombosis in the postintervention group (20% vs 8%; P = .07), which was not significantly different when accounting for acuity of VTE. Management adherence was strong, at 91%, in the postintervention group. Conclusion The ISTH guidance on management of cancer‐associated thrombosis in patients with thrombocytopenia was successfully implemented in an academic medical center. There was no significant difference in bleeding or recurrent thrombosis outcomes after adjusting for acuity of VTE. |
| first_indexed | 2024-03-12T19:11:02Z |
| format | Article |
| id | doaj.art-582833a7d6ae47c28568e2205e3162fd |
| institution | Directory Open Access Journal |
| issn | 2475-0379 |
| language | English |
| last_indexed | 2024-03-12T19:11:02Z |
| publishDate | 2022-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Research and Practice in Thrombosis and Haemostasis |
| spelling | doaj.art-582833a7d6ae47c28568e2205e3162fd2023-08-02T05:55:06ZengElsevierResearch and Practice in Thrombosis and Haemostasis2475-03792022-05-0164n/an/a10.1002/rth2.12726Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statementNicole Held0Benjamin Jung1Lisa Baumann Kreuziger2Division of Hematology/Oncology, Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USAFroedtert Hospital Milwaukee Wisconsin USADivision of Hematology/Oncology, Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USAAbstract Background Optimal management of cancer‐associated thrombosis (CAT) in patients with thrombocytopenia remains difficult given competing risks of recurrent thrombosis and increased bleeding. We determine the impact of the ISTH Scientific and Standardization Committee (SCC) guidance on CAT management and thrombocytopenia on platelet transfusion, bleeding, and recurrent thrombosis. Methods A retrospective review was performed of patients with CAT and thrombocytopenia who required anticoagulation for VTE for 11 months before and after implementation of the ISTH SCC guidance. Medical records were reviewed to identify the type of VTE event, number of platelet transfusions, incidence of bleeding, and VTE recurrence within pre‐ and postintervention time periods. Results A total of 41 and 80 cases were included in the preintervention and postintervention periods, respectively. The preintervention group showed a trend toward less acute VTE events (39% vs 55%; P = .05). The postintervention period had an increased per‐patient platelet transfusion (median, 2.5 vs 4; P = .05). Nonmajor bleeding was increased in the postintervention group (2% vs 16%; P = 0.03) and included all six (8%) major hemorrhages (P = .09). There was numerically less recurrent thrombosis in the postintervention group (20% vs 8%; P = .07), which was not significantly different when accounting for acuity of VTE. Management adherence was strong, at 91%, in the postintervention group. Conclusion The ISTH guidance on management of cancer‐associated thrombosis in patients with thrombocytopenia was successfully implemented in an academic medical center. There was no significant difference in bleeding or recurrent thrombosis outcomes after adjusting for acuity of VTE.https://doi.org/10.1002/rth2.12726anticoagulantshemorrhageplatelet countplatelet transfusionthrombocytopeniathrombosis |
| spellingShingle | Nicole Held Benjamin Jung Lisa Baumann Kreuziger Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement Research and Practice in Thrombosis and Haemostasis anticoagulants hemorrhage platelet count platelet transfusion thrombocytopenia thrombosis |
| title | Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement |
| title_full | Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement |
| title_fullStr | Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement |
| title_full_unstemmed | Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement |
| title_short | Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement |
| title_sort | management of cancer associated thrombosis with thrombocytopenia impact of the isth guidance statement |
| topic | anticoagulants hemorrhage platelet count platelet transfusion thrombocytopenia thrombosis |
| url | https://doi.org/10.1002/rth2.12726 |
| work_keys_str_mv | AT nicoleheld managementofcancerassociatedthrombosiswiththrombocytopeniaimpactoftheisthguidancestatement AT benjaminjung managementofcancerassociatedthrombosiswiththrombocytopeniaimpactoftheisthguidancestatement AT lisabaumannkreuziger managementofcancerassociatedthrombosiswiththrombocytopeniaimpactoftheisthguidancestatement |